Efektivitas Inositol dan Metformin pada Sindrom Ovarium Polikistik (PCOS): Tinjauan Sistematis dari Uji Klinis Acak Terkontrol

Widya Puspita Sari; Daivan Febri Juan Setiya; Dinda Ashilah Putri Kusnan; Hani’a Fauza; Riyas Hasan Yazid; Meidy Zulvan Prabowo

doi:10.61132/protein.v3i3.1416

Authors

Widya Puspita Sari Universitas Islam Indonesia
Daivan Febri Juan Setiya Universitas Islam Indonesia
Dinda Ashilah Putri Kusnan Universitas Gadjah Mada
Hani’a Fauza Universitas Islam Indonesia
Riyas Hasan Yazid Universitas Islam Indonesia
Meidy Zulvan Prabowo Universitas Islam Indonesia

DOI:

https://doi.org/10.61132/protein.v3i3.1416

Keywords:

Myo-inositol

Abstract

of reproductive age, characterized by insulin resistance (IR), anovulation, and hyperandrogenism, often leading to infertility. Metformin is the first-line therapy used. However, inositol, especially myo-inositol (MI) and D-chiro-inositol (DCI), have shown promising therapeutic potential. Direct comparison and optimal efficacy of both still require a comprehensive review. Objective: This systematic review aims to evaluate the efficacy of inositol (as monotherapy or in combination) compared with metformin, placebo, or no intervention, in improving reproductive, hormonal, and metabolic outcomes in women with PCOS. Methods: Conducted according to PRISMA guidelines, a systematic literature search was conducted in Pubmed and Ebsco databases for randomized controlled trials (RCTs) published in the last 10 years. Studies evaluating inositol and/or metformin in women with PCOS and reporting reproductive, hormonal, or metabolic outcomes were included. Study selection and data extraction were performed independently by five reviewers. Results: Six randomized controlled trials (RCTs) were included in this review. Metformin consistently showed improvements in insulin resistance and androgen levels. Myo-inositol also demonstrated efficacy in improving metabolic and hormonal parameters, as well as reproductive outcomes, often with a better tolerability profile, especially as monotherapy. The combination of metformin and myo-inositol has shown potential improvements in some reproductive functions (such as live birth rate) compared to metformin alone in some studies. However, other studies have shown comparable or superior efficacy of myo-inositol monotherapy with fewer side effects. Adjuvant therapies such as dexamethasone or calcium/vitamin D have shown benefits in certain subpopulations. Conclusions: Both inositol (especially myo-inositol) and metformin have significant therapeutic roles in the management of PCOS. Metformin remains an important intervention for metabolic dysregulation and hyperandrogenism. Inositol appears to be an effective and often better tolerated alternative, with significant reproductive benefits. The choice of therapy should be individualized based on patient phenotype and treatment goals.

Downloads

Download data is not yet available.

References

Abdalla, M. A., Shah, N., Deshmukh, H., Sahebkar, A., Östlundh, L., Al-Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2022). Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. Therapeutic Advances in Endocrinology and Metabolism, 13. https://doi.org/10.1177/20420188221127142

Agrawal, A., Mahey, R., Kachhawa, G., Khadgawat, R., Vanamail, P., & Kriplani, A. (2019). Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecological Endocrinology, 35(6), 511–514. https://doi.org/10.1080/09513590.2018.1549656

El-Garhi, I. T., El-Omda, F. A. A., El-Khatib, G. Z., & Awad, A. M. F. (2019). Effect of Metformin Only versus Effect of Metformin and Corticosteroids after Laparoscopic Ovarian Drilling on Ovulation in Women with Clomiphene Citrate Resistant Polycystic Ovary Syndrome. The Egyptian Journal of Hospital Medicine, 74(1), 63–69. https://doi.org/10.21608/ejhm.2019.22433

Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270–284. https://doi.org/10.1038/nrendo.2018.24

Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaddiparthi, V., Witchel, S. F., Pena, A., Spritzer, P. M., Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism, 109(6), 1630–1655. https://doi.org/10.1210/clinem/dgad762

Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., Várbíró, S., & Horváth, E. M. (2023). Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology, 21(1), 10. https://doi.org/10.1186/s12958-023-01055-z

Kadoura, S., Alhalabi, M., & Nattouf, A. H. (2019). Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Menstrual Cycle Abnormalities, Hormonal Profile, and IGF-1 System in Polycystic Ovary Syndrome Patients: A Randomized, Placebo-Controlled Clinical Trial. Advances in Pharmacological Sciences, 2019, 1–10. https://doi.org/10.1155/2019/9680390

Pateguana, N. B., & Janes, A. (2019). The contribution of hyperinsulinemia to the hyperandrogenism of polycystic ovary syndrome. Journal of Metabolic Health, 4(1). https://doi.org/10.4102/jir.v4i1.50

Prabhakar, P., Mahey, R., Gupta, M., Khadgawat, R., Kachhawa, G., Sharma, J. B., Vanamail, P., Kumari, R., & Bhatla, N. (2021). Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial. Gynecological Endocrinology, 37(4), 332–336. https://doi.org/10.1080/09513590.2020.1810657

Shamim, H., Jean, M., Umair, M., Muddaloor, P., Farinango, M., Ansary, A., Dakka, A., Nazir, Z., White, C. T., Habbal, A. B., & Mohammed, L. (2022). Role of Metformin in the Management of Polycystic Ovarian Syndrome-Associated Acne: A Systematic Review. Cureus. https://doi.org/10.7759/cureus.28462

Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023). Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. Journal of Clinical Medicine, 12(4), 1454. https://doi.org/10.3390/jcm12041454

Sohrevardi, S. M., Nosouhi, F., Khalilzade, S. H., Kafaie, P., Karimi-Zarchi, M., Halvaei, I., & Mohsenzadeh, M. (2016). Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. International Journal of Reproductive BioMedicine, 14(12), 743–754. https://doi.org/10.29252/ijrm.14.12.743

Tariq, A., Mir, M. A., Babar, S., & Akhtar, R. (2018). PCOS. The Professional Medical Journal, 25(04), 568–572. https://doi.org/10.29309/TPMJ/2018.25.04.348

Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections, 6(8), 647–658. https://doi.org/10.1530/EC-17-0243

Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023). Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. Journal of Ovarian Research, 16(1), 9. https://doi.org/10.1186/s13048-022-01091-0